On August 28, BioNTech SE fell 8.22% in regular trading, trading at $101.89/share, with turnover of $61.24 million.

On the news front, the company announced the termination of its Phase 2 Autogene Cevumeran colorectal cancer immunotherapy trial, a core pipeline in its mRNA oncology portfolio. The termination represents a significant setback to BioNTech's strategic pivot from COVID-19 vaccines toward cancer immunotherapy.

Compounding the negative sentiment, while Pfizer and BioNTech received FDA approval for their COVID-19 vaccine targeting the XFG variant, the authorized population was limited to adults aged 65 and older and individuals aged 5 through 64 with at least one high-risk underlying condition. This marks a substantial narrowing from prior approvals that covered the general population, further pressuring the company's COVID vaccine revenue outlook.

Within the Biotechnology sector, Moderna declined 3.62%, Alnylam Pharmaceuticals fell 4.46%, Insmed dropped 2.68%, and AbbVie lost 0.78%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)